Compare Neurocrine Biosciences Inc (NBIX) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nucor Corporation — how do they compare? Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B), while Nucor Corporation trades at $248.12 (market cap $55.84B). The key difference: Nucor Corporation is far larger — about 3.9× Neurocrine Biosciences Inc's market cap, and Nucor Corporation pays a 0.91% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Nucor Corporation for 78 Days on average.
| NBIX | NUE | |
|---|---|---|
Market Cap | $14.36B | $55.84B |
Volume | 1,237,180 | 848,835 |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $274.74 |
52-Week Low | $123.10 | $131.78 |
Typical Hold Time | 23 Days | 78 Days |
Enterprise Value | $14.37B | $60.25B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Nucor (NUE) trades at $246.44, down 1.84% on the day, with a neutral technical signal and mixed earnings history including a Q2 2026 beat. Revenue and net income have shown volatility, with 2025 revenue at $32.49B and net income at $1.74B, while analyst consensus is a 'Buy' with a $266.88 price target. Recent news highlights steel sector dynamics and Nucor's Q3 2026 earnings guidance.
The outlook for NUE is cautiously optimistic, supported by analyst bullishness and projected earnings growth, but risks include competitive pressures from new steel capacity and cyclical demand fluctuations. Investment opportunity lies in its solid fundamentals and dividend history, though investors should weigh margin pressures and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
